Lymph Node Ratio As a Survival Risk Factor for Oropharyngeal Squamous Cell Carcinoma Patients with Lymph Node Metastasis: A SEER-based Analysis
Y. L. Wang,Guanhua Zhu,D. S. Li,Y. Wang,Z. Y. Wang,Qinghai Ji
2013-01-01
Head & Neck Oncology
Abstract:Purpose To study the impact of lymph node ratio (the number of involved nodes divided by the number of nodes examined) on the prognosis of oropharyngeal cancer. Patients and methods Surveillance, epidemiology and end results-registered oropharyngeal cancer patients with detailed lymph node metastasis information (n = 4935) were evaluated using a multivariate Cox regression analysis to identify the prognostic role of the lymph node ratio in oropharyngeal cancer. Results Multivariate analysis identified the race, year of diagnosis, primary site, histological type, radiation sequence with surgery, tumour node metastasis classification, continuous lymph node ratio (hazard ratio 1.279, 95% confidence interval 1.037–1.579) and age as prognostic variables that were associated with cause-specific survival in oropharyngeal cancer. When patients were classified into 3 risk groups as R1 (lymph node ratio ≤0.04), R2 (lymph node ratio 0.04–0.14) and R3 (lymph node ratio >0.14), the 5-year cause-specific survival and overall survival rates were 83.3%, 72.9% and 67.4% and 74.9%, 65.2% and 57.6%, respectively. The cause-specific survival and overall survival curves of individual R classification patients diagnosed after 1995 were clearly separated compared with those of the N classification. When the N2 patients (accounting for 67.6% of the total patients) were stratified into three groups as R1 (n = 508), R2 (n = 1156) and R3 (n = 1672), the 5-year causespecific survival rates (log rank χ2 88.053, p<0.001) and overall survival rates (log rank χ2 90.974, p<0.001) for the three groups were 86.5%, 73.6% and 63.9% and 77.5%, 65.5% and 53.8%, respectively. Conclusion Lymph node ratio is a significant prognostic factor for the survival of oropharyngeal cancer patients and should be used for postoperative staging to complement the N classification of oropharyngeal cancer. Introduction The oropharynx includes the base of the tongue, tonsils, soft palate and posterior pharyngeal wall. Oropharyngeal cancer has been increasing in prevalence over the past decade1. Surgery with and without adjuvant treatment or definitive chemoradiotherapy are the two main treatment options for oropharyngeal cancer. To avoid open surgical resection that disrupts the musculoskeletal infrastructure of the oral cavity and pharynx, resulting in potential disfigurement and swallowing dysfunction, the treatment paradigm for oropharyngeal cancer has shifted towards primary chemoradiation2,3. However, minimally invasive surgical approaches, including transoral laser microsurgery (TLM) and transoral robotic surgery, have been gaining momentum based on excellent oncological and functional outcomes, not only for early-stage but also for stage III and stage IV oropharyngeal cancer1,4–8. Transoral resection with ipsilateral level II to IV neck dissection is also recommended as a gold standard for stage I and stage II invasive squamous cell carcinoma of the tonsillar region, which can spare the use of radiotherapy to eliminate late effects and permit its use for the subsequent management of metachronous head and neck second primary cancer9. Using the nationwide inpatient sample database, the temporal trends in oropharyngeal cancer surgical care were evaluated in 75828 cases, which demonstrated a significant increase in the total number of oropharyngeal cancer surgical cases in the past decade and a decrease in the use of primary site ablative procedures2. When surgery was selected for management of oropharyngeal cancer, the postoperative risk stratification was important for choosing the adjuvant treatment. The purposes of cancer staging are to predict patient prognosis, guide treatment, evaluate treatment results, direct research and convey information between physicians. For postoperative staging, the tumour node metastasis (TNM) system defined by the American Joint Committee on Cancer dominates clinical practice today. In a retrospective analysis of 3891 oropharyngeal * Corresponding author E-mail: jiqinghai@shca.org.cn 1 Department of Head & Neck Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China 2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China 3 Department of Radiation Oncology, Cancer Hospital, Fudan University, Shanghai 200032, China Original research study Page 2 of 10 Co m pe n g in te re st s: n on e de cl ar ed . C on fl i ct o f i nt er es ts : n on e de cl ar ed . A ll au th or s co nt rib ut ed to th e co nc ep o n, d es ig n, a nd p re pa ra o n of th e m an us cr ip t, a s w el l a s re ad a nd a pp ro ve d th e fi n al m an us cr ip t. A ll au th or s ab id e by th e A ss oc ia o n fo r M ed ic al E th ic s (A M E) e th ic al ru le s of d is cl os ur e. Licensee OA Publishing London 2013. Creative Commons Attribution Licence (CC-BY) F : Wang YL, Zhu GP, Li DS, Wang Y, Wang ZY, Ji QH. Lymph node ratio as a survival risk factor for oropharyngeal squamous cell carcinoma patients with lymph node metastasis: A surveillance, epidemiology and end results-based analysis. Head Neck Oncol. 2013 Feb 28;5(3):30. cancer cases treated at the University of Texas, MD Anderson Cancer Center, TNM staging predicted the survival of patients who received treatment before 1995, but not those treated between 1995 and 20043. The use of tobacco and human papillomavirus (HPV) status also affected survival of oropharyngeal cancer patients in recent studies, and their incorporation into the oropharyngeal cancer staging system has been recommended3,10,11. Currently, there is no uniformly accepted formula for combining multiple well-defined independent prognostic factors. The oropharynx is extremely rich in lymphatics. Depending on the subsite involved, 15%–75% of patients present with lymph node involvement1. The lymph node ratio (LNR), defined as the number of involved nodes divided by the number of lymph nodes examined, has been found to improve prognostic information in breast cancer, gastric cancer, colorectal cancer, melanoma and other cancers12–15. To the best of our knowledge, there have been no previous reports describing the use of LNR for predicting survival of patients with oropharyngeal cancer. In the current study, the prognostic role of LNR was analysed in surveillance, epidemiology and end results (SEER)-registered oropharyngeal cancer patients with lymph node metastasis. In addition, the cut-off points for LNR in defining patients as high risk, medium risk or low risk were also identified. Methods and materials Patients The SEER Cancer Statistics Review, a report on the most recent cancer incidence, mortality, survival, prevalence and lifetime risk statistics, is published annually by the Data Analysis and Interpretation Branch of the National Cancer Institute16. SEER collects and publishes these statistics from population-based registries covering 26% of the United States population. The 17 SEER registries routinely collect data on patient demographics, primary tumour site, tumour morphology, extent of disease, first course of treatment and active follow-up for vital status16. The SEER database has been widely used for the analysis of LNR staging of breast, colon, gastric, and other cancers17–19. Cases of oropharyngeal carcinoma from 1988 to 2008 were extracted from the SEER database (SEER*Stat 7.0.5) according to the site recode classifications. Cancers were limited to the tonsils, oropharynx and base of the tongue, which were defined as the tonsillar fossa (C09.0), tonsillar pillar (C09.1), overlapping lesion of tonsil (C09.8), tonsil none of specific (NOS, C09.9), vallecula (C10.0), anterior surface of epiglottis (C10.1), lateral wall of oropharynx (C10.2), posterior wall of oropharynx (C10.3), branchial cleft (C10.4), overlapping lesion of oropharynx (C10.8), oropharynx NOS (C10.9), base of tongue NOS (C01.9) and lingual tonsil (C02.4). Histology was limited to squamous cell carcinoma (histology recode– broad groupings 02). LNR was calculated as the number of positive regional nodes (1988+) divided by the number of regional nodes examined (1988+). The cases with discordant N classification information and the number of positive regional lymph nodes recorded in the SEER database were rejected. Because the aim of current study was to identify the role of LNR staging for oropharyngeal cancer, cases with unclassified T classification, M classification, grade and other variables were also enrolled in the analysis set and were defined as Tx, Mx and unknown group to avoid losing information and selection bias. Finally, a total of 4935 cases of pN+ oropharyngeal carcinoma with detailed lymph node staging information were collected as the analysis set. This study was approved by the Fudan University, Shanghai Cancer Center ethics review board. Statistical analysis Statistical comparisons of different factors related to SEER cause-specific survival (CSS) and overall survival (OS) were performed using the log rank χ2 test. Using the Kaplan–Meier method, the survival curves were plotted and survival rates were calculated. All the risk factors associated with CSS were enrolled in a multivariate regression analysis using a Cox proportional hazards model. In the first step, we evaluated the prognostic value of LNR as a continuous variable, adjusting for other covariates associated with CSS in 4935 cases of pN+ oropharyngeal cancer. For daily clinical use, we proceeded to determine the most appropriate cut-off points for categorizing LNR into high-risk, medium-risk and lowrisk groups, and compared the predictive accuracy for survival between the categorical and the continuous LNR. The first pair of cut-off points was identified by means of tertiles of continuous LNR. The second pair of cut-off points was analysed using the X-tile program (http://www.tissuearray.org/rimmlab/), which identified the cut-off with the minimum p values from log rank χ2 statistics for the categorical LNR in terms of survival14,20. Harrell